Cargando…
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour‐necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biolo...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587715/ https://www.ncbi.nlm.nih.gov/pubmed/30411382 http://dx.doi.org/10.1111/apt.14997 |